Cisplatin 75mg/m2

DRUG2 trials

Sponsors

Hangzhou ACEA Pharmaceutical Research Co., Ltd., Inhibrx Biosciences, Inc

Conditions

Gastric CancerHead and Neck CancerMelanomaNSCLCNon-Small Cell Lung CancerRenal Cell CarcinomaResectable Non-Small-Cell Lung CancerSolid Tumor

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RecruitingNCT04198766

Inhibrx Biosciences, IncSolid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer +5

Start: 2019-12-10End: 2033-07-01Target: 340Updated: 2026-07-29

Phase 3

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

WithdrawnNCT03058094

Hangzhou ACEA Pharmaceutical Research Co., Ltd.NSCLC

Start: 2018-12-31End: 2020-01-31Updated: 2019-02-04

Related Papers

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Journal for ImmunoTherapy of Cancer2025-05-014 citations

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Regular and Young Investigator Award Abstracts2023-10-311 citations

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice

Regular and Young Investigator Award Abstracts2023-10-31

856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

Regular and Young Investigator Award Abstracts2021-11-019 citations